.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: RE39155

« Back to Dashboard

Claims for Patent: RE39155

Title:Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B
Abstract:Use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of hepatitis B is disclosed. ##STR00001##
Inventor(s): Belleau; Pierrette (Montreal, CA), Nguyen-Ba; Nghe (La Praire, CA), Belleau; Bernard (Westmont, CA)
Assignee: Shire BioChem Inc. (Quebec, CA)
Application Number:09/585,431
Patent Claims: 1. A method for the treatment of .Iadd.hepatitis B infection, in .Iaddend.a mammal, including a human, suffering from hepatitis B infection, comprising administration of an effective amount of a compound of formula (I) ##STR00005## or a pharmaceutically acceptable salt, ester, or salt of an ester thereof to said mammal.

2. The method according to claim 1 wherein the hepatitis B infection is human hepatitis B.

3. The method according to claim 1 wherein the compound of formula (I) comprises (.+-.)-cis-4-amino-1-( 2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt, ester, or salt of an ester thereof.

4. The method according to claim 1 wherein the compound of formula (I) comprises (-)-cis-4-amino-1-( 2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt, ester, or salt of an ester thereof.

5. The method according to claim 4 wherein the compound of formula (I) is substantially free of the corresponding (+)-enantiomer.

6. The method according to any one of claims 1 to 5 wherein the compound of formula (I) is adapted for oral administration.

7. The method according to any one of claims 1 to 5 wherein the compound of formula (I) is adapted for parenteral administration.

8. The method according to any one of claims 1 to 5 wherein the compound of formula (I) is in unit dosage form.

9. The method according to claim 8 wherein the compound is present in an amount of from 10 to 1500 mg.

.Iadd.10. A method for the treatment of hepatitis B infection, in a human, suffering from hepatitis B infection, comprising administering to said human an effective amount of a compound of formula (I) ##STR00006## or a pharmaceutically acceptable salt, ester, or salt of an ester thereof. .Iaddend.

.Iadd.11. The method according to claim 10, wherein the compound of formula (I) is (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-- one or a pharmaceutically acceptable salt, ester or salt of an ester thereof. .Iaddend.

.Iadd.12. A method for the treatment of hepatitis B infection, in a human, suffering from hepatitis B infection, comprising administering to said human an effective amount of a compound of formula (I) ##STR00007## or a pharmaceutically acceptable salt thereof. .Iaddend.

.Iadd.13. The method according to claim 12, wherein the compound of formula (I) is (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-- one or a pharmaceutically acceptable salt thereof. .Iaddend.

.Iadd.14. The method according to claim 10, comprising administering a compound of formula (I). .Iaddend.

.Iadd.15. The method according to claim 13, comprising administering (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-- one. .Iaddend.

.Iadd.16. The method according to claim 11, wherein the (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-- one or pharmaceutically acceptable salt thereof is substantially free of the corresponding (+)-enantiomer. .Iaddend.

.Iadd.17. The method according to claim 13, wherein the (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-- one or pharmaceutically acceptable salt thereof is substantially free of the corresponding (+)-enantiomer. .Iaddend.

.Iadd.18. The method according to claim 15, wherein the (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-- one is substantially free of the corresponding (+)-enantiomer. .Iaddend.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc